For some students, the technology can effectively replace collaborative learning with classmates and office hours with professors.

BY RANDIMA ATTYGALLE In a collaborative international provenance research, which was concluded in April 2022, six artefacts from the Rijksmuseum collection in Amsterdam, were confirmed to be of Lankan ...

OPINION It’s hardly a revelation that AI has grown exponentially.  While seizing the imagination—and resources--of investors, ...

Q2 2025 Earnings Call Transcript June 4, 2025 REV Group, Inc. beats earnings expectations. Reported EPS is $0.7, expectations were $0.59. Operator: Greetings, and welcome to REV Group, Inc.’s Second ...

first-in-class PD-1/IL-2 α-bias bispecific antibody fusion protein, for the treatment of "immune cold tumor" —immunotherapy-pretreated melanoma (acral and mucosal subtypes) were orally ...

announces that the clinical data of IBI363 (first-in-class PD-1/IL-2 α-bias bispecific antibody fusion protein) monotherapy and combo-therapy with bevacizumab in advanced colorectal cancer were ...

Progressive Grocer’s 2025 Top Women in Grocery awards program recognizes the integral role women play across all segments of ...

We will continue to advance the clinical exploration of IBI363 in NSCLC and other tumor types." IBI363 is a first-in-class PD-1/IL-2 α-bias bispecific antibody fusion protein independently developed ...

About IBI363 (First-in-class PD-1/IL-2α-bias bispecific antibody fusion protein) IBI363 is a first-in-class PD-1/IL-2α-bias bispecific antibody fusion protein independently developed by Innovent ...

CCM Biosciences, a diversified pharmaceutical discovery and development company, today announced the upcoming presentation of its 4th-generation EGFR inhibitor drug program for non-small cell lung ...